Aligos Therapeutics Q2 2025 Earnings Report

Aligos Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$2.35
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aligos Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.43 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aligos Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 5, 2025
• Conference Call Time: 12:30PM ET

Aligos Therapeutics (NASDAQ:ALGS) (NASDAQ: ALGS) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapeutics for the treatment of viral diseases and liver disorders. Headquartered in South San Francisco, California, Aligos is advancing a pipeline of both small molecule and nucleic acid-based programs designed to achieve functional cures or meaningful clinical improvements in patients with chronic hepatitis B virus (HBV) infection and nonalcoholic steatohepatitis (NASH).

The company’s research engine integrates cutting-edge chemistry, immunology and RNA biology to create targeted therapies that address multiple stages of the viral lifecycle and modulate host immune responses. Lead programs include orally administered inhibitors that target HBV replication and novel RNA interference (RNAi) assets aimed at silencing viral and fibrotic pathways in the liver. Preclinical candidates are also being evaluated for their potential to enhance antiviral immunity and reverse liver fibrosis in NASH patients.

Founded in 2014, Aligos has drawn on venture capital support and strategic partnerships to build its scientific platform and advance assets through clinical development. The company went public in 2020, listing its shares on the NASDAQ under the ticker ALGS. Since inception, Aligos has maintained a commitment to rigorous translational research, leveraging in-house manufacturing capabilities and external collaborations to optimize its drug candidates for safety, potency and delivery.

Aligos conducts its clinical trials across the United States, Europe and Asia, engaging leading medical centers and patient communities to generate robust data in diverse populations. The company is led by a team of seasoned biotechnology executives and scientific leaders with extensive experience in virology, hepatology and drug development. Together, they aim to deliver transformational therapies that address significant unmet needs in chronic liver disease and viral infection.